- Home
- WAVE vs ALXO Comparison
WAVE vs ALXO Comparison
Compare WAVE & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WAVE
- ALXO
- Stock Information
- Founded
- WAVE 2011
- ALXO 2015
- Country
- WAVE Israel
- ALXO United States
- Employees
- WAVE N/A
- ALXO N/A
- Industry
- WAVE Electric Utilities: Central
- ALXO Biotechnology: Pharmaceutical Preparations
- Sector
- WAVE Utilities
- ALXO Health Care
- Exchange
- WAVE Nasdaq
- ALXO Nasdaq
- Market Cap
- WAVE 64.4M
- ALXO 76.5M
- IPO Year
- WAVE 2021
- ALXO 2020
- Fundamental
- Price
- WAVE $10.37
- ALXO $1.74
- Analyst Decision
- WAVE
- ALXO Buy
- Analyst Count
- WAVE 0
- ALXO 6
- Target Price
- WAVE N/A
- ALXO $11.00
- AVG Volume (30 Days)
- WAVE 83.1K
- ALXO 1.1M
- Earning Date
- WAVE 11-21-2024
- ALXO 03-06-2025
- Dividend Yield
- WAVE N/A
- ALXO N/A
- EPS Growth
- WAVE N/A
- ALXO N/A
- EPS
- WAVE N/A
- ALXO N/A
- Revenue
- WAVE $279,000.00
- ALXO N/A
- Revenue This Year
- WAVE N/A
- ALXO N/A
- Revenue Next Year
- WAVE N/A
- ALXO N/A
- P/E Ratio
- WAVE N/A
- ALXO N/A
- Revenue Growth
- WAVE 933.33
- ALXO N/A
- 52 Week Low
- WAVE $1.01
- ALXO $1.19
- 52 Week High
- WAVE $17.63
- ALXO $17.83
- Technical
- Relative Strength Index (RSI)
- WAVE 46.80
- ALXO 53.13
- Support Level
- WAVE $8.00
- ALXO $1.56
- Resistance Level
- WAVE $11.46
- ALXO $1.94
- Average True Range (ATR)
- WAVE 1.43
- ALXO 0.16
- MACD
- WAVE -0.21
- ALXO -0.01
- Stochastic Oscillator
- WAVE 38.54
- ALXO 50.00
About WAVE Eco Wave Power Global AB (publ)
Eco Wave Power Global AB is a Sweden-based wave energy company engaged in the development of a smart and cost-efficient WEC, technology that converts ocean and sea waves into clean electricity. Its WEC technology employs units of point absorber floating devices, referred to as floaters, which are installed on existing marine structures such as piers, breakwaters, and jetties, or in locations in which such marine structures are required. Geographical presence in Israel, USA and Mexico.
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.